AI Retinal Diagnostics Market
完整報告名稱與涵蓋範圍
AI Retinal Diagnostics Market Size, Share & Trends Analysis Report, By Product (Autonomous AI Diagnostic Software, AI-Assisted Retinal Screening and Triage Software, Retinal Imaging Devices with Embedded AI (Fundus Cameras and Handheld Devices), Image Enhancement, Quality Assessment and Workflow Software), By Application (Diabetic Retinopathy Screening, Age-Related Macular Degeneration and Glaucoma Detection, Systemic Disease Risk Assessment (Cardiovascular, Renal and Neurological), Retinopathy of Prematurity and Pediatric Screening), By End User (Primary Care and Diabetes Clinics, Ophthalmology and Optometry Practices, Hospitals, Health Systems and Screening Programs, Retail Optical and Pharmacy Settings), By Region, and Segment Forecasts, 2026-2035
報告摘要
The AI retinal diagnostics market covers autonomous and assistive AI software that detects diabetic retinopathy, macular degeneration, glaucoma and other retinal disease from fundus and optical coherence tomography images, retinal imaging devices with embedded AI, and image enhancement, quality assessment and workflow software, including emerging applications that estimate systemic cardiovascular, renal and neurological risk from retinal images. Fundus image enhancement software, which is not a separately measurable revenue pool, is included within this scope. Conventional retinal cameras without AI and ophthalmic treatment devices are excluded.
The category was validated by the first autonomous AI diagnostic clearance and dedicated reimbursement codes for diabetic retinopathy screening in primary care, which addressed the persistent gap in annual eye exams among people with diabetes. Adoption is expanding through handheld and low-cost cameras that bring screening to pharmacies, community clinics and retail optical settings, through health system programs that combine screening with care gap closure and through national screening initiatives in Europe and Asia. Vendors are extending algorithms to multiple diseases, to optical coherence tomography and to systemic risk prediction, while regulatory classification, reimbursement outside the United States, camera-software compatibility and validation across populations shape competition.
North America leads reimbursed adoption, with the United Kingdom, Singapore, India and China operating large screening programs and Europe expanding. Competition involves autonomous AI specialists, retinal imaging device manufacturers, technology groups with ophthalmic AI programs and low-cost camera innovators from emerging markets.
The InsightAce study supplies US$ forecasts for all product, application and end user and regional segments over 2026-2035, segment-level trend analysis, competitive landscape assessment and profiling of the leading companies.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global AI Retinal Diagnostics Market Snapshot
Chapter 4. Global AI Retinal Diagnostics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Product Estimates & Trend Analysis
5.1. Product & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Product:
5.2.1. Autonomous AI Diagnostic Software
5.2.2. AI-Assisted Retinal Screening and Triage Software
5.2.3. Retinal Imaging Devices with Embedded AI (Fundus Cameras and Handheld Devices)
5.2.4. Image Enhancement, Quality Assessment and Workflow Software
Chapter 6. Market Segmentation 2: By Application Estimates & Trend Analysis
6.1. Application & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Application:
6.2.1. Diabetic Retinopathy Screening
6.2.2. Age-Related Macular Degeneration and Glaucoma Detection
6.2.3. Systemic Disease Risk Assessment (Cardiovascular, Renal and Neurological)
6.2.4. Retinopathy of Prematurity and Pediatric Screening
Chapter 7. Market Segmentation 3: By End User Estimates & Trend Analysis
7.1. End User & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
7.2.1. Primary Care and Diabetes Clinics
7.2.2. Ophthalmology and Optometry Practices
7.2.3. Hospitals, Health Systems and Screening Programs
7.2.4. Retail Optical and Pharmacy Settings
Chapter 8. AI Retinal Diagnostics Market: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. United States
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. United Kingdom
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Asia Pacific
8.3.1. China
8.3.2. Japan
8.3.3. India
8.3.4. South Korea
8.3.5. Australia
8.3.6. Southeast Asia
8.3.7. Rest of Asia Pacific
8.4. Latin America
8.4.1. Brazil
8.4.2. Mexico
8.4.3. Rest of Latin America
8.5. Middle East & Africa
8.5.1. GCC Countries
8.5.2. South Africa
8.5.3. Rest of Middle East & Africa
Chapter 9. Competitive Landscape
9.1. Company Market Positioning Analysis
9.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 10. Company Profiles
10.1. Digital Diagnostics Inc.
10.2. Eyenuk, Inc.
10.3. AEYE Health Inc.
10.4. Optomed Oyj
10.5. Topcon Healthcare
10.6. Carl Zeiss Meditec AG
10.7. Retmarker S.A.
10.8. Mediwhale Inc.
10.9. Toku Inc.
10.10. RetinAI Medical AG
10.11. Google LLC (Verily and DeepMind Health Programs)
10.12. Remidio Innovative Solutions Pvt. Ltd.
10.13. Airdoc Technology Co., Ltd.
10.14. Eyetelligence (Optain Health)
10.15. Heidelberg Engineering GmbH
圖表清單 List of Tables & Figures
Table 1. Global AI Retinal Diagnostics Revenue Forecast by Product, 2026-2035 (US$ Mn)
Figure 1. Global AI Retinal Diagnostics Market Snapshot, 2026 & 2035
Table 2. Global AI Retinal Diagnostics Revenue Forecast by Application, 2026-2035 (US$ Mn)
Figure 2. Global AI Retinal Diagnostics Market Share by Application, 2026 & 2035
Table 3. Global AI Retinal Diagnostics Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 3. Diabetic Retinopathy Screening Gap and AI-Enabled Screening Coverage by Region, 2026-2035
Table 4. North America AI Retinal Diagnostics Revenue by Country, 2026-2035 (US$ Mn)
Figure 4. AI Retinal Diagnostic Applications from Diabetic Retinopathy to Systemic Disease Risk
Table 5. Europe AI Retinal Diagnostics Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific AI Retinal Diagnostics Growth Opportunity Analysis
Table 6. Asia Pacific AI Retinal Diagnostics Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Deployment Settings for AI Retinal Screening: Primary Care, Retail and Community Programs
Table 7. Latin America and Middle East & Africa AI Retinal Diagnostics Revenue Forecast, 2026-2035 (US$ Mn)
Figure 7. Competitive Positioning of Key AI Retinal Diagnostics Market Participants
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們